NEWAMSTERDAM PHARMA CO NV (NAMS) Stock News
NASDAQ:NAMS - Nasdaq - NL00150012L7 - Common Stock - Currency: USD
NAMS Latest News, Press Relases and Analysis
NewAmsterdam Pharma Company N.V. (NAMS) Initiated with a Buy at Stifel
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifel’s coverage, with a buy rating and a $44 price target. According to the firm, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a distinct late-stage cardiovascular company with a short-term trajectory toward regulatory filings. Its core […]
Merck’s Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. The medication is being studied as a potential treatment for hyperlipidemia, a condition […]
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
-- Pre-specified analyses show that obicetrapib treatment leads to statistically significant and clinically meaningful reductions in the primary outcome...
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NAARDEN, the Netherlands and MIAMI, May 27, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 132.5% in NewAmsterdam Pharma Company N.V. (NAMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) delivered earnings and revenue surprises of -8.89% and 7.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MGX
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 200% and 26.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: AKBA
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at...
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
– Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, the Netherlands and MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”),...
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein...
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential
We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) stands against other billionaire Andreas Halvorsen’s stock picks with huge upside potential. Ole Andreas Halvorsen is one of the prominent names among […]
Is NewAmsterdam Pharma Company N.V. (NAMS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?
We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier after the initial panic […]
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
NewAmsterdam Pharma (NAMS): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Stanley Druckenmiller’s Top 10 Stocks Picks with Huge Upside Potential. In this article, we are going to take a look at where NewAmsterdam Pharma Company N.V (NASDAQ:NAMS) stands against other Billionaire Stanley Druckenmiller’s other top stock picks with huge upside potential. Wall Street is overflowing with data. If […]
Nissan sells its Indian plant to Renault to raise cash
Sale is part of broader restructuring of the Alliance.
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9.
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the...
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- ...